After seeing four of its patents for its Symbicort tossed aside, AstraZeneca has gained a key victory in defense of its blockbuster inhaler. A federal court in West Virginia upheld the company’s claim ...
Symbicort and Advair are similar brand-name prescription medications that treat asthma and COPD. They contain slightly different active ingredients. Symbicort and Advair are two drugs that treat ...
The price you pay for Symbicort may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. You may be able to lower your long-term costs by getting a ...
AstraZeneca’s aging respiratory giant Symbicort won a coveted pediatric exclusivity nod from the FDA on Wednesday, giving the brand a longer life—and potentially hundreds of millions in additional ...
Viatris Inc. VTRS announced that the company and partner Kindeva Drug Delivery L.P. have won a court decision that invalidates AstraZeneca's AZN patent for Symbicort. The U.S. District Court for the ...
LONDON, Oct 29 (Reuters) - AstraZeneca Plc's asthma drug Symbicort can also improve lung function in patients with "smoker's lung", or chronic obstructive pulmonary disease (COPD), results of two ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320/9 µg twice daily had a safety profile similar to ...
AstraZeneca AZN announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol. Symbicort is a combination formulation containing budesonide, an inhaled ...
New data showed that using SYMBICORT® for asthma provides a rapid and clinically significant bronchodilatory response and improvement in lung function. New data showed that using SYMBICORT® for asthma ...
The government is taking steps to curb use of some long-acting asthma drugs taken by millions, issuing safety restrictions Thursday to lower an uncommon but potentially life-threatening risk that ...
The US Food and Drug Administration has approved AstraZeneca's Symbicort inhalation aerosol (80/4.5 mcg) for children aged 6 to 12 years with asthma that is not well controlled with an inhaled ...
LONDON, Oct 18 (Reuters) - AstraZeneca Plc lost a key European patent on its two-in-one asthma drug Symbicort on Thursday but the drugmaker said it did not expect the move to have an immediate impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results